Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan 31;22(1):15.
doi: 10.1186/s13058-020-1252-7.

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

Alberto Ocaña  1   2   3 , Eitan Amir  4 , Atanasio Pandiella  5   6
Affiliations
Review

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

Alberto Ocaña et al. Breast Cancer Res. .

Abstract

Background: There has been substantial interest in HER2 intratumoral heterogeneity as an explanation for the development of resistance to anti-HER2 therapies in breast cancer, particularly to trastuzumab emtansine (T-DM1).

Methods: Through a literature-based approach, we discuss mechanisms of resistance to HER2-targeting antibody-drug conjugates (ADCs) in breast cancer.

Results: We describe results from clinical studies reporting the effect of anti-HER2 strategies particularly ADCs and their mechanistic effect. We review biological findings underlying HER2 heterogeneity and its implication in the development of novel anti-HER2 drugs including new ADCs in clinical development like trastuzumab deruxtecan (DS-8201).

Conclusions: We suggest potential mechanisms to optimize these compounds and their future clinical implementation.

Keywords: ADCs; DS-8201; HER2 heterogeneity; HER2 resistance; T-DM1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182. doi: 10.1126/science.3798106. - DOI - PubMed
    1. Wolff AC, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105–2122. doi: 10.1200/JCO.2018.77.8738. - DOI - PubMed
    1. Esparis-Ogando A, Montero JC, Arribas J, Ocana A, Pandiella A. Targeting the EGF/HER ligand-receptor system in cancer. Curr Pharm Des. 2016;22:5887–5898. doi: 10.2174/1381612822666160715132233. - DOI - PubMed
    1. Hurvitz Sara A., Martin Miguel, Jung Kyung Hae, Huang Chiun-Sheng, Harbeck Nadia, Valero Vicente, Stroyakovskiy Daniil, Wildiers Hans, Campone Mario, Boileau Jean-François, Fasching Peter A., Afenjar Karen, Spera Gonzalo, Lopez-Valverde Vanesa, Song Chunyan, Trask Peter, Boulet Thomas, Sparano Joseph A., Symmans W. Fraser, Thompson Alastair M., Slamon Dennis. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. Journal of Clinical Oncology. 2019;37(25):2206–2216. doi: 10.1200/JCO.19.00882. - DOI - PMC - PubMed

Publication types